BMS declines option for F-star's FS102

F-star Biotechnology Ltd. (Cambridge, U.K.) said Bristol-Myers Squibb Co. (NYSE:BMY) will not exercise an option to acquire F-star Alpha Ltd. (Cambridge, U.K.) and its single asset, FS102, ending the companies' partnership. F-star Biotechnology CEO John Haurum told BioCentury the company will decide what to do with the HER2-targeted Fc antibody fragment “in a few months” once it has data from a Phase I trial in patients with breast and gastric cancer. F-star Biotechnology said BMS terminated the agreement based on “prioritization of opportunities across its oncology portfolio.”...